Analyst Ratings February 13, 2026

Bernstein SocGen Lifts Cognex Target to $66, Citing Early-Stage Factory Automation Upswing

Analysts diverge on valuation even as Cognex posts strong Q4 and signals of margin gains persist

By Marcus Reed CGNX
Bernstein SocGen Lifts Cognex Target to $66, Citing Early-Stage Factory Automation Upswing
CGNX

Bernstein SocGen raised its price objective for Cognex to $66 from $49 and kept an Outperform rating, pointing to what it sees as the early phases of a global factory automation recovery and sustained margin expansion. The company's shares have climbed substantially year-to-date and over the past 12 months, while other brokerages have issued a range of views on the stock's prospects and valuation.

Key Points

  • Bernstein SocGen raised its price target on Cognex to $66 from $49 and maintained an Outperform rating, citing an early-stage factory automation upswing and expected margin expansion through 2027.
  • Cognex shares jumped 36% in one session and are trading near a 52-week high after delivering 74.5% return over the past year and roughly 63.1% year-to-date.
  • Analyst opinions diverge: Raymond James raised its target to $80 (Strong Buy), Goldman Sachs upgraded to Buy with a $50 target, while JPMorgan downgraded to Underweight and set a $35 target.

Bernstein SocGen has increased its price target for Cognex Corp. to $66.00 from $49.00 and continues to carry an Outperform rating on the machine vision specialist. The firm’s revision comes as Cognex shares have already moved sharply higher, trading around $57.28 at the time of the latest update, with analyst price targets on the street spanning between $35 and $80.

The stock experienced a notable one-day advance, jumping 36% on Thursday after company commentary and execution signaled a cyclical recovery in global factory automation demand. Management also outlined a concrete action plan tied to higher profit margin targets, which helped fuel investor enthusiasm. Over the past year, the shares have returned 74.5% and are trading close to a 52-week high of $59.88.

Bernstein SocGen acknowledged that Cognex has already rallied roughly 60% year-to-date yet still sees room for additional upside as it views the factory automation upcycle to be in its early stages. Year-to-date performance has been strong, with a reported 63.1% gain so far. At the same time, technical indicators have drawn some caution; one market signal suggests the stock’s relative strength index is in overbought territory.

On the fundamentals, Bernstein SocGen expects margin expansion to persist at least through 2027 and credits the new management team with transitioning Cognex from a technology startup trajectory toward a more mature business model capable of low-teen growth rates. The research team also recommended that Cognex pursue adjacent opportunities - specifically sensors and robotic path planning - "more decisively" as a next strategic step.

These views come amid a flurry of analyst re-evaluations following Cognex’s fourth-quarter report, which beat expectations on both revenue and earnings per share. Raymond James singled out especially strong results in the Logistics segment, and in response raised its price target to $80 while maintaining a Strong Buy recommendation.

Goldman Sachs moved to upgrade its stance on Cognex from Sell to Buy and set a new target of $50, pointing to improved growth prospects tied to rising automation demand. Goldman expects growth to be driven by increased logistics automation as well as a recovery in the consumer electronics and packaging end markets.

In contrast, JPMorgan trimmed its rating on Cognex from Neutral to Underweight, citing valuation concerns and lowering its target to $35. While JPMorgan acknowledged the stock’s promising long-term outlook, the firm emphasized cyclical risks as a reason for a more cautious near-term stance.

The mix of bullish and bearish analyst moves illustrates differing perspectives on how quickly automation end markets will recover, how sustainably margins can expand, and how much valuation multiple expansion is justified at current price levels.


Key points

  • Bernstein SocGen raised its price target to $66 from $49 and maintained an Outperform rating, citing an early-stage global factory automation upcycle and continued margin expansion.
  • Cognex stock has rallied strongly - up about 63.1% year-to-date and 74.5% over the past year - with the share price trading near its 52-week high following a 36% one-day surge.
  • Other broker moves are mixed: Raymond James raised its target to $80 and kept Strong Buy; Goldman Sachs upgraded to Buy with a $50 target; JPMorgan downgraded to Underweight with a $35 target.

Risks and uncertainties

  • Valuation risk - JPMorgan explicitly cited valuation concerns as the reason for a downgrade, indicating the stock may be vulnerable if market sentiment shifts.
  • Cyclical exposure - Analysts highlighted exposure to cyclical end markets such as factory automation, consumer electronics and packaging, creating sensitivity to demand swings.
  • Technical overbought signal - A relative strength indicator flagged the stock as potentially overbought, which could presage a near-term pullback.

Risks

  • Valuation concerns raised by JPMorgan could limit upside and increase downside risk for investors in Cognex, affecting equity markets tied to automation.
  • Cyclical demand in factory automation, consumer electronics and packaging presents uncertain revenue timing and potential volatility for Cognex and related industrial suppliers.
  • Technical indicators suggest the stock may be overbought, introducing the risk of a short-term pullback that could affect trading activity in industrial and logistics technology equities.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026